Get started
Author

Binliang Liu

The relationship between statins and breast cancer prognosis varies by statin type and exposure time: a meta-analysis
2017 · Binliang Liu, Zongbi Yi, et al. · Breast Cancer Research and Treatment · 122
Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer
2020 · Zongbi Yi, Guohua Rong, et al. · npj Breast Cancer · 71
PDF
Overexpressed SIRT6 ameliorates doxorubicin-induced cardiotoxicity and potentiates the therapeutic efficacy through metabolic remodeling
2023 · Kezheng Peng, Chenye Zeng, et al. · Acta Pharmaceutica Sinica B · 52
The molecular tumor burden index as a response evaluation criterion in breast cancer
2021 · Zongbi Yi, Fei Ma, et al. · Signal Transduction and Targeted Therapy · 51
PDF
Gut Microbiota Profiling in Patients With HER2-Negative Metastatic Breast Cancer Receiving Metronomic Chemotherapy of Capecitabine Compared to Those Under Conventional Dosage
2020 · Xiuwen Guan, Fei Ma, et al. · Frontiers in Oncology · 51
PDF
Longitudinal HER2 amplification tracked in circulating tumor DNA for therapeutic effect monitoring and prognostic evaluation in patients with breast cancer
2019 · Xiuwen Guan, Binliang Liu, et al. · The Breast · 41
PDF
Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study
2019 · Zongbi Yi, Fei Ma, et al. · BMC Cancer · 33
PDF
The circulating tumor DNA (ctDNA) alteration level predicts therapeutic response in metastatic breast cancer: Novel prognostic indexes based on ctDNA
2022 · Binliang Liu, Zheyu Hu, et al. · The Breast · 31
Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER ‐targeted therapy in HER2 amplification‐positive and HER2 mutation‐positive amplification‐negative patients
2022 · Binliang Liu, Zongbi Yi, et al. · Cancer Medicine · 31
PDF
Landscape of somatic mutations in different subtypes of advanced breast cancer with circulating tumor DNA analysis
2017 · Zongbi Yi, Fei Ma, et al. · Scientific Reports · 30
PDF
Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor-positive breast cancer and the exploration of biomarkers
2020 · Zongbi Yi, Binliang Liu, et al. · The Breast · 28
The association between early‐onset cardiac events caused by neoadjuvant or adjuvant chemotherapy in triple‐negative breast cancer patients and some novel autophagy‐related polymorphisms in their genomic DNA: a real‐world study
2018 · Binliang Liu, Tao An, et al. · 癌症：英文版 · 26
PDF
Development and Validation of a New Clinical Prediction Model of Catheter-Related Thrombosis Based on Vascular Ultrasound Diagnosis in Cancer Patients
2020 · Binliang Liu, Junying Xie, et al. · Frontiers in Cardiovascular Medicine · 20
PDF
Pyrotinib in combination with letrozole for hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer (PLEHERM): a multicenter, single-arm, phase II trial
2023 · Zhe-Yu Hu, Min Yan, et al. · BMC Medicine · 17
PDF
Epithelial-Mesenchymal-Transition-Like Circulating Tumor Cell-Associated White Blood Cell Clusters as a Prognostic Biomarker in HR-Positive/HER2-Negative Metastatic Breast Cancer
2021 · Xiuwen Guan, Chunxiao Li, et al. · Frontiers in Oncology · 15
PDF
Genome-wide chromosomal instability by cell-free DNA sequencing predicts survival in patients with metastatic breast cancer
2020 · Hongnan Mo, Xiaobing Wang, et al. · The Breast · 15
Exploring the clinical outcomes and safety profile of inetetamab treatment in metastatic breast cancer patients: A multicenter assessment of a Chinese-origin recombinant Anti-HER2 monoclonal antibody
2023 · Binliang Liu, Ning Xie, et al. · The Breast · 11
PDF
Investigating cardiovascular diseases related to endocrine therapy in hormone receptor-positive early breast cancer: insights from a nationwide real-world study
2025 · Cheng Zeng, Hong Li, et al. · Cardio-Oncology · 9
PDF
Beyond clinical trials: CDK4/6 inhibitor efficacy predictors and nomogram model from real‐world evidence in metastatic breast cancer
2024 · Binliang Liu, Zhe‐Yu Hu, et al. · Cancer Innovation · 9
PDF
Plasma cell‑free DNA and survival in non‑small‑cell lung cancer: A meta‑analysis
2017 · Zongbi Yi, Binliang Liu, et al. · Molecular and Clinical Oncology · 9
PDF
Subtyping of metastatic breast cancer based on plasma circulating tumor DNA alterations: An observational, multicentre platform study
2022 · Zhe-Yu Hu, Yu Tang, et al. · EClinicalMedicine · 8
Breast cancer metastases to the thyroid and stomach: A case report
2023 · Xue Bai, Canbin Fang, et al. · Oncology Letters · 7
PDF
Impact of HER2 mutation status on personalized molecular targeted therapy in advanced breast cancers.
2018 · Zongbi Yi, Fei Ma, et al. · Journal of Clinical Oncology · 7
Circulating tumor DNA profile and its clinical significance in patients with hormone receptor-positive and HER2-negative mBC
2022 · Yu Tang, Jing Li, et al. · Frontiers in Endocrinology · 6
Clinical value of next-generation sequencing in guiding decisions regarding endocrine therapy for advanced HR-positive/HER-2-negative breast cancer
2022 · Dan Lyu, Binliang Liu, et al. · Chinese Journal of Cancer Research · 6
Works count: 69
Citation count: 747
H-index: 15
I10-index: 17
Year
Topic
Type